[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3Kd5WjenwUnpIrnqJAjlfsBw7OzdrA2pqwvNiLwkGYA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"West Virginia University",[4,6],"West Virginia University Healthcare",149,false,32,5,10202,22,93,[15,18,20,23,25,27,29,32],{"name":16,"count":17},"Sleep Quality",7,{"name":19,"count":10},"Breast Cancer",{"name":21,"count":22},"Obesity",3,{"name":24,"count":22},"Hypertension",{"name":26,"count":22},"Glaucoma",{"name":28,"count":22},"Glioblastoma",{"name":30,"count":31},"Accidental Falls",2,{"name":33,"count":31},"Hip Osteoarthritis",[35,40,45,50,54,59,64,69,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04953780","2157GCCC:Phase 1 of Calaspargase Pegol-mknl W\u002F Cytarabine and Idarubicin in Newly Dx AML","2025-12-31","Calaspargase pegol-mknl",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07210697","Orthodontic Pain Alleviation With Chewing Gum","2026-03","Xylitol Gum",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04922723","Radiation\u002FTemozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma","2026-12","Daratumumab",{"nctId":51,"briefTitle":52,"date":48,"intervention":53},"NCT05013255","Pioglitazone Therapy Targeting Fatigue in Breast Cancer","Pioglitazone 15mg",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06820164","Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride","2027-01","Cooled Sodium Chloride",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04911816","Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma","2027-06","Hydroxychloroquine sulfate",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07148960","Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","2027-07","Early Dual IV Antibiotic Therapy - MRSA",{"nctId":70,"briefTitle":71,"date":67,"intervention":72},"NCT07401277","Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum","5% 5-fluorouracil (5-FU) powder",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06923488","Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes","2027-10","Leflunomide 10mg",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05430035","Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma","2027-12","HIPEC",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,118,136,154,172,194,217,235,257,278,302,320,338,364,391,413,431,458,476,497,519,537,559,613,635,657,683,710,728,757,782,800,823,849,867,893,920,944,962,988,1006,1031,1049,1075,1093,1124,1142,1168,1194,1222,1246,1272,1298,1316,1340,1365,1383,1406,1431,1456,1474,1499,1523,1547,1565,1588,1623,1646,1670,1694,1719,1737,1762,1786,1809,1832,1857,1875],{"intervention":68,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":116},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":67},[105],{"nctId":65,"briefTitle":66,"status":106,"phases":107,"primaryCompletion":67,"completion":67,"start":108,"enrollment":109,"conditions":110,"interventions":112},"ENROLLING_BY_INVITATION",[88],"2025-09-15",300,[111],"Staphylococcus Aureus Bacteremia",[68,113,114,115],"Early Dual IV Antibiotic Therapy - MSSA","Single Agent IV Antibiotic Therapy - MRSA","Single Agent IV Antibiotic Therapy - MSSA",{"trials":117,"activeCount":96},[],{"intervention":113,"totalTrials":92,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":134},{"trials":121,"activeCount":96},[],{"trials":123,"activeCount":96},[],{"trials":125,"activeCount":96},[],{"trials":127,"activeCount":96},[],{"trials":129,"activeCount":92,"soonestReadout":67},[130],{"nctId":65,"briefTitle":66,"status":106,"phases":131,"primaryCompletion":67,"completion":67,"start":108,"enrollment":109,"conditions":132,"interventions":133},[88],[111],[68,113,114,115],{"trials":135,"activeCount":96},[],{"intervention":114,"totalTrials":92,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":152},{"trials":139,"activeCount":96},[],{"trials":141,"activeCount":96},[],{"trials":143,"activeCount":96},[],{"trials":145,"activeCount":96},[],{"trials":147,"activeCount":92,"soonestReadout":67},[148],{"nctId":65,"briefTitle":66,"status":106,"phases":149,"primaryCompletion":67,"completion":67,"start":108,"enrollment":109,"conditions":150,"interventions":151},[88],[111],[68,113,114,115],{"trials":153,"activeCount":96},[],{"intervention":115,"totalTrials":92,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":170},{"trials":157,"activeCount":96},[],{"trials":159,"activeCount":96},[],{"trials":161,"activeCount":96},[],{"trials":163,"activeCount":96},[],{"trials":165,"activeCount":92,"soonestReadout":67},[166],{"nctId":65,"briefTitle":66,"status":106,"phases":167,"primaryCompletion":67,"completion":67,"start":108,"enrollment":109,"conditions":168,"interventions":169},[88],[111],[68,113,114,115],{"trials":171,"activeCount":96},[],{"intervention":44,"totalTrials":92,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":190,"NA":192},{"trials":175,"activeCount":96},[],{"trials":177,"activeCount":96},[],{"trials":179,"activeCount":96},[],{"trials":181,"activeCount":92,"soonestReadout":43},[182],{"nctId":41,"briefTitle":42,"status":183,"phases":184,"primaryCompletion":43,"completion":43,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NOT_YET_RECRUITING",[87],"2025-10",60,[188],"Orthodontic Appliances",[44],{"trials":191,"activeCount":96},[],{"trials":193,"activeCount":96},[],{"intervention":58,"totalTrials":92,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":197,"activeCount":96},[],{"trials":199,"activeCount":96},[],{"trials":201,"activeCount":92,"soonestReadout":57},[202],{"nctId":55,"briefTitle":56,"status":203,"phases":204,"primaryCompletion":57,"completion":57,"start":205,"enrollment":206,"conditions":207,"interventions":209},"RECRUITING",[85,86],"2025-05-08",20,[208],"Lipoma",[58,210],"Warmed Sodium Chloride",{"trials":212,"activeCount":96},[],{"trials":214,"activeCount":96},[],{"trials":216,"activeCount":96},[],{"intervention":210,"totalTrials":92,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":229,"PHASE4":231,"NA":233},{"trials":220,"activeCount":96},[],{"trials":222,"activeCount":96},[],{"trials":224,"activeCount":92,"soonestReadout":57},[225],{"nctId":55,"briefTitle":56,"status":203,"phases":226,"primaryCompletion":57,"completion":57,"start":205,"enrollment":206,"conditions":227,"interventions":228},[85,86],[208],[58,210],{"trials":230,"activeCount":96},[],{"trials":232,"activeCount":96},[],{"trials":234,"activeCount":96},[],{"intervention":63,"totalTrials":92,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":238,"activeCount":96},[],{"trials":240,"activeCount":96},[],{"trials":242,"activeCount":92,"soonestReadout":62},[243],{"nctId":60,"briefTitle":61,"status":203,"phases":244,"primaryCompletion":62,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},[85,86],"2030-06","2021-07-16",40,[249],"Adenocarcinoma of the Pancreas",[63],{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":96},[],{"trials":256,"activeCount":96},[],{"intervention":49,"totalTrials":92,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":260,"activeCount":96},[],{"trials":262,"activeCount":96},[],{"trials":264,"activeCount":92,"soonestReadout":48},[265],{"nctId":46,"briefTitle":47,"status":266,"phases":267,"primaryCompletion":48,"completion":48,"start":268,"enrollment":269,"conditions":270,"interventions":271},"ACTIVE_NOT_RECRUITING",[85,86],"2022-10-03",16,[28],[49],{"trials":273,"activeCount":96},[],{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":96},[],{"intervention":77,"totalTrials":92,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":296,"PHASE4":298,"NA":300},{"trials":281,"activeCount":96},[],{"trials":283,"activeCount":96},[],{"trials":285,"activeCount":92,"soonestReadout":76},[286],{"nctId":74,"briefTitle":75,"status":203,"phases":287,"primaryCompletion":76,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},[85,86],"2028-10","2025-07-15",26,[292],"Myelodysplastic Syndromes",[77,294,295],"Leflunomide 20mg","Decitabine",{"trials":297,"activeCount":96},[],{"trials":299,"activeCount":96},[],{"trials":301,"activeCount":96},[],{"intervention":294,"totalTrials":92,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":305,"activeCount":96},[],{"trials":307,"activeCount":96},[],{"trials":309,"activeCount":92,"soonestReadout":76},[310],{"nctId":74,"briefTitle":75,"status":203,"phases":311,"primaryCompletion":76,"completion":288,"start":289,"enrollment":290,"conditions":312,"interventions":313},[85,86],[292],[77,294,295],{"trials":315,"activeCount":96},[],{"trials":317,"activeCount":96},[],{"trials":319,"activeCount":96},[],{"intervention":295,"totalTrials":92,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":323,"activeCount":96},[],{"trials":325,"activeCount":96},[],{"trials":327,"activeCount":92,"soonestReadout":76},[328],{"nctId":74,"briefTitle":75,"status":203,"phases":329,"primaryCompletion":76,"completion":288,"start":289,"enrollment":290,"conditions":330,"interventions":331},[85,86],[292],[77,294,295],{"trials":333,"activeCount":96},[],{"trials":335,"activeCount":96},[],{"trials":337,"activeCount":96},[],{"intervention":339,"totalTrials":92,"cells":340},"Eravacycline",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":342,"activeCount":96},[],{"trials":344,"activeCount":96},[],{"trials":346,"activeCount":92,"soonestReadout":351},[347],{"nctId":348,"briefTitle":349,"status":203,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":357},"NCT05537896","Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia",[86],"2028-02","2024-02-19",55,[355,356],"Hematological Malignancy","Neutropenia",[339],{"trials":359,"activeCount":96},[],{"trials":361,"activeCount":96},[],{"trials":363,"activeCount":96},[],{"intervention":365,"totalTrials":92,"cells":366},"Subcutaneous Blinatumomab",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":96},[],{"trials":372,"activeCount":92,"soonestReadout":377},[373],{"nctId":374,"briefTitle":375,"status":203,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":384},"NCT07222579","Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)",[86],"2029-08","2031-08","2026-01-15",78,[382,383],"CD19 Positive","Mixed Phenotype Acute Leukemia (MPAL)",[365],{"trials":386,"activeCount":96},[],{"trials":388,"activeCount":96},[],{"trials":390,"activeCount":96},[],{"intervention":53,"totalTrials":92,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":394,"activeCount":96},[],{"trials":396,"activeCount":96},[],{"trials":398,"activeCount":92,"soonestReadout":48},[399],{"nctId":51,"briefTitle":52,"status":203,"phases":400,"primaryCompletion":48,"completion":48,"start":401,"enrollment":402,"conditions":403,"interventions":405},[86],"2021-12-23",30,[19,404],"Muscle Fatigue",[53,406],"Pioglitazone 30 mg",{"trials":408,"activeCount":96},[],{"trials":410,"activeCount":96},[],{"trials":412,"activeCount":96},[],{"intervention":406,"totalTrials":92,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":416,"activeCount":96},[],{"trials":418,"activeCount":96},[],{"trials":420,"activeCount":92,"soonestReadout":48},[421],{"nctId":51,"briefTitle":52,"status":203,"phases":422,"primaryCompletion":48,"completion":48,"start":401,"enrollment":402,"conditions":423,"interventions":424},[86],[19,404],[53,406],{"trials":426,"activeCount":96},[],{"trials":428,"activeCount":96},[],{"trials":430,"activeCount":96},[],{"intervention":432,"totalTrials":92,"cells":433},"Cannabidiol (CBD) Oil 300mg",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":435,"activeCount":96},[],{"trials":437,"activeCount":92,"soonestReadout":442},[438],{"nctId":439,"briefTitle":440,"status":203,"phases":441,"primaryCompletion":442,"completion":443,"start":444,"enrollment":109,"conditions":445,"interventions":448},"NCT06686914","The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex",[85],"2028-12-31","2029-05-01","2025-06-30",[446,447],"Cannabidiol Effects","Driving Performance",[432,449],"Cannabidiol (CBD) Oil 150mg",{"trials":451,"activeCount":96},[],{"trials":453,"activeCount":96},[],{"trials":455,"activeCount":96},[],{"trials":457,"activeCount":96},[],{"intervention":449,"totalTrials":92,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":461,"activeCount":96},[],{"trials":463,"activeCount":92,"soonestReadout":442},[464],{"nctId":439,"briefTitle":440,"status":203,"phases":465,"primaryCompletion":442,"completion":443,"start":444,"enrollment":109,"conditions":466,"interventions":467},[85],[446,447],[432,449],{"trials":469,"activeCount":96},[],{"trials":471,"activeCount":96},[],{"trials":473,"activeCount":96},[],{"trials":475,"activeCount":96},[],{"intervention":39,"totalTrials":92,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":479,"activeCount":96},[],{"trials":481,"activeCount":92,"soonestReadout":38},[482],{"nctId":36,"briefTitle":37,"status":266,"phases":483,"primaryCompletion":38,"completion":38,"start":484,"enrollment":485,"conditions":486,"interventions":488},[85],"2021-09-27",6,[487],"Acute Myeloid Leukemia",[39],{"trials":490,"activeCount":96},[],{"trials":492,"activeCount":96},[],{"trials":494,"activeCount":96},[],{"trials":496,"activeCount":96},[],{"intervention":72,"totalTrials":92,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":517},{"trials":500,"activeCount":96},[],{"trials":502,"activeCount":92,"soonestReadout":67},[503],{"nctId":70,"briefTitle":71,"status":203,"phases":504,"primaryCompletion":67,"completion":505,"start":506,"enrollment":9,"conditions":507,"interventions":509},[85],"2027-08","2026-02-06",[508],"Actinic Keratoses",[72,510],"5% 5-fluorouracil",{"trials":512,"activeCount":96},[],{"trials":514,"activeCount":96},[],{"trials":516,"activeCount":96},[],{"trials":518,"activeCount":96},[],{"intervention":510,"totalTrials":92,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":529,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":522,"activeCount":96},[],{"trials":524,"activeCount":92,"soonestReadout":67},[525],{"nctId":70,"briefTitle":71,"status":203,"phases":526,"primaryCompletion":67,"completion":505,"start":506,"enrollment":9,"conditions":527,"interventions":528},[85],[508],[72,510],{"trials":530,"activeCount":96},[],{"trials":532,"activeCount":96},[],{"trials":534,"activeCount":96},[],{"trials":536,"activeCount":96},[],{"intervention":82,"totalTrials":92,"cells":538},{"EARLY_PHASE1":539,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":540,"activeCount":92,"soonestReadout":81},[541],{"nctId":79,"briefTitle":80,"status":203,"phases":542,"primaryCompletion":81,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},[84],"2029-07","2022-06-23",10,[547],"Gallbladder Adenocarcinoma",[82],{"trials":550,"activeCount":96},[],{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[],{"trials":556,"activeCount":96},[],{"trials":558,"activeCount":96},[],{"intervention":560,"totalTrials":22,"cells":561},"Sugammadex",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":578,"PHASE4":580,"NA":611},{"trials":563,"activeCount":96},[],{"trials":565,"activeCount":96},[],{"trials":567,"activeCount":96},[568],{"nctId":569,"briefTitle":570,"status":571,"phases":572,"primaryCompletion":573,"completion":573,"start":574,"enrollment":96,"conditions":575,"interventions":577},"NCT05664633","The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures","WITHDRAWN",[85,86],"2024-06","2023-08",[576],"Postoperative Urinary Retention",[560],{"trials":579,"activeCount":96},[],{"trials":581,"activeCount":96},[582,597],{"nctId":583,"briefTitle":584,"status":585,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":594},"NCT03111121","Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy","COMPLETED",[88],"2018-06-22","2019-05-30","2017-05-04",79,[592,593],"Microlaryngoscopy","Rigid Bronchoscopy",[560,595,596],"neostigmine","glycopyrrolate",{"nctId":598,"briefTitle":599,"status":585,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":607},"NCT03939923","Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery",[88],"2021-07-30","2019-05-01",84,[605,606],"Surgery","Coronary Artery Disease",[608,609,610,560],"Rocuronium","Neostigmine","Glycopyrrolate",{"trials":612,"activeCount":96},[],{"intervention":595,"totalTrials":31,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":623,"NA":633},{"trials":616,"activeCount":96},[],{"trials":618,"activeCount":96},[],{"trials":620,"activeCount":96},[],{"trials":622,"activeCount":96},[],{"trials":624,"activeCount":96},[625,629],{"nctId":583,"briefTitle":584,"status":585,"phases":626,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":627,"interventions":628},[88],[592,593],[560,595,596],{"nctId":598,"briefTitle":599,"status":585,"phases":630,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":631,"interventions":632},[88],[605,606],[608,609,610,560],{"trials":634,"activeCount":96},[],{"intervention":596,"totalTrials":31,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":655},{"trials":638,"activeCount":96},[],{"trials":640,"activeCount":96},[],{"trials":642,"activeCount":96},[],{"trials":644,"activeCount":96},[],{"trials":646,"activeCount":96},[647,651],{"nctId":583,"briefTitle":584,"status":585,"phases":648,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":649,"interventions":650},[88],[592,593],[560,595,596],{"nctId":598,"briefTitle":599,"status":585,"phases":652,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":653,"interventions":654},[88],[605,606],[608,609,610,560],{"trials":656,"activeCount":96},[],{"intervention":658,"totalTrials":92,"cells":659},"Cefazolin",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":681},{"trials":661,"activeCount":96},[],{"trials":663,"activeCount":96},[],{"trials":665,"activeCount":96},[],{"trials":667,"activeCount":96},[],{"trials":669,"activeCount":96},[670],{"nctId":671,"briefTitle":672,"status":571,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":96,"conditions":676,"interventions":680},"NCT01880112","Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.",[88],"2013-06","2011-06",[677,678,679],"Infection","Cesarean Delivery","Antibiotic Prophylaxis",[658],{"trials":682,"activeCount":96},[],{"intervention":684,"totalTrials":92,"cells":685},"Betamethasone",{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":694,"NA":708},{"trials":687,"activeCount":96},[],{"trials":689,"activeCount":96},[],{"trials":691,"activeCount":96},[],{"trials":693,"activeCount":96},[],{"trials":695,"activeCount":96},[696],{"nctId":697,"briefTitle":698,"status":585,"phases":699,"primaryCompletion":700,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT04900220","Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections",[88],"2022-12-27","2023-04-10","2021-09-15",66,[705],"Trigger Finger",[684,707],"Methylprednisolone",{"trials":709,"activeCount":96},[],{"intervention":707,"totalTrials":92,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":726},{"trials":713,"activeCount":96},[],{"trials":715,"activeCount":96},[],{"trials":717,"activeCount":96},[],{"trials":719,"activeCount":96},[],{"trials":721,"activeCount":96},[722],{"nctId":697,"briefTitle":698,"status":585,"phases":723,"primaryCompletion":700,"completion":701,"start":702,"enrollment":703,"conditions":724,"interventions":725},[88],[705],[684,707],{"trials":727,"activeCount":96},[],{"intervention":729,"totalTrials":92,"cells":730},"Sodium bicarbonate",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":755},{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":96},[],{"trials":736,"activeCount":96},[],{"trials":738,"activeCount":96},[],{"trials":740,"activeCount":96},[741],{"nctId":742,"briefTitle":743,"status":744,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":22,"conditions":748,"interventions":754},"NCT04530448","Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization","TERMINATED",[88],"2021-07-15","2020-10-05",[749,750,751,752,753],"COVID","Coronavirus","Coronavirus Infection","AKI","Acute Kidney Injury",[729],{"trials":756,"activeCount":96},[],{"intervention":758,"totalTrials":92,"cells":759},"Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":780},{"trials":761,"activeCount":96},[],{"trials":763,"activeCount":96},[],{"trials":765,"activeCount":96},[],{"trials":767,"activeCount":96},[],{"trials":769,"activeCount":96},[770],{"nctId":771,"briefTitle":772,"status":744,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":10,"conditions":776,"interventions":778},"NCT05156437","Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)",[88],"2024-10-31","2022-03-16",[777],"Endocarditis",[758,779],"Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline",{"trials":781,"activeCount":96},[],{"intervention":779,"totalTrials":92,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":798},{"trials":785,"activeCount":96},[],{"trials":787,"activeCount":96},[],{"trials":789,"activeCount":96},[],{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[794],{"nctId":771,"briefTitle":772,"status":744,"phases":795,"primaryCompletion":774,"completion":774,"start":775,"enrollment":10,"conditions":796,"interventions":797},[88],[777],[758,779],{"trials":799,"activeCount":96},[],{"intervention":801,"totalTrials":92,"cells":802},"Cosopt",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":821},{"trials":804,"activeCount":96},[],{"trials":806,"activeCount":96},[],{"trials":808,"activeCount":96},[],{"trials":810,"activeCount":96},[],{"trials":812,"activeCount":96},[813],{"nctId":814,"briefTitle":815,"status":585,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":545,"conditions":819,"interventions":820},"NCT00379834","12-Month Stability of Diurnal IOP Control on Cosopt",[88],"2008-04","2006-09",[26],[801],{"trials":822,"activeCount":96},[],{"intervention":824,"totalTrials":92,"cells":825},"Dexamethasone",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":834,"NA":847},{"trials":827,"activeCount":96},[],{"trials":829,"activeCount":96},[],{"trials":831,"activeCount":96},[],{"trials":833,"activeCount":96},[],{"trials":835,"activeCount":96},[836],{"nctId":837,"briefTitle":838,"status":585,"phases":839,"primaryCompletion":840,"completion":841,"start":842,"enrollment":380,"conditions":843,"interventions":845},"NCT03711474","Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)",[88],"2023-07-30","2024-07-30","2018-09-07",[844],"Dysphagia",[824,846],"Saline",{"trials":848,"activeCount":96},[],{"intervention":846,"totalTrials":92,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":865},{"trials":852,"activeCount":96},[],{"trials":854,"activeCount":96},[],{"trials":856,"activeCount":96},[],{"trials":858,"activeCount":96},[],{"trials":860,"activeCount":96},[861],{"nctId":837,"briefTitle":838,"status":585,"phases":862,"primaryCompletion":840,"completion":841,"start":842,"enrollment":380,"conditions":863,"interventions":864},[88],[844],[824,846],{"trials":866,"activeCount":96},[],{"intervention":868,"totalTrials":92,"cells":869},"Nicotine Replacement Therapy Agent",{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":891},{"trials":871,"activeCount":96},[],{"trials":873,"activeCount":96},[],{"trials":875,"activeCount":96},[],{"trials":877,"activeCount":96},[],{"trials":879,"activeCount":96},[880],{"nctId":881,"briefTitle":882,"status":571,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":96,"conditions":887,"interventions":890},"NCT06350175","Emergency Department Management of Tobacco Use Disorder",[88],"2025-03","2025-06","2024-08",[888,889],"Tobacco Use Disorder","Tobacco Use Cessation",[868],{"trials":892,"activeCount":96},[],{"intervention":894,"totalTrials":92,"cells":895},"Sufentanil",{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":918},{"trials":897,"activeCount":96},[],{"trials":899,"activeCount":96},[],{"trials":901,"activeCount":96},[],{"trials":903,"activeCount":96},[],{"trials":905,"activeCount":96},[906],{"nctId":907,"briefTitle":908,"status":571,"phases":909,"primaryCompletion":910,"completion":910,"start":911,"enrollment":96,"conditions":912,"interventions":917},"NCT04464512","Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population",[88],"2021-08-22","2020-01-10",[913,914,915,916],"Addiction Opiate","Chronic Pain","Fractures, Bone","Buprenorphine Dependence",[894],{"trials":919,"activeCount":96},[],{"intervention":921,"totalTrials":92,"cells":922},"Piperacillin-tazobactam combination product",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":942},{"trials":924,"activeCount":96},[],{"trials":926,"activeCount":96},[],{"trials":928,"activeCount":96},[],{"trials":930,"activeCount":96},[],{"trials":932,"activeCount":96},[933],{"nctId":934,"briefTitle":935,"status":744,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":485,"conditions":939,"interventions":941},"NCT01694069","Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis",[88],"2013-09","2012-09",[940],"Cystic Fibrosis",[921],{"trials":943,"activeCount":96},[],{"intervention":608,"totalTrials":92,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":960},{"trials":947,"activeCount":96},[],{"trials":949,"activeCount":96},[],{"trials":951,"activeCount":96},[],{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[956],{"nctId":598,"briefTitle":599,"status":585,"phases":957,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":958,"interventions":959},[88],[605,606],[608,609,610,560],{"trials":961,"activeCount":96},[],{"intervention":963,"totalTrials":92,"cells":964},"Dexmedetomidine",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":986},{"trials":966,"activeCount":96},[],{"trials":968,"activeCount":96},[],{"trials":970,"activeCount":96},[],{"trials":972,"activeCount":96},[],{"trials":974,"activeCount":96},[975],{"nctId":976,"briefTitle":977,"status":585,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":981,"conditions":982,"interventions":984},"NCT02604940","Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients",[88],"2018-06-25","2014-08",46,[983],"Pain",[963,985],"Normal Saline",{"trials":987,"activeCount":96},[],{"intervention":985,"totalTrials":92,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1004},{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":96},[],{"trials":995,"activeCount":96},[],{"trials":997,"activeCount":96},[],{"trials":999,"activeCount":96},[1000],{"nctId":976,"briefTitle":977,"status":585,"phases":1001,"primaryCompletion":979,"completion":979,"start":980,"enrollment":981,"conditions":1002,"interventions":1003},[88],[983],[963,985],{"trials":1005,"activeCount":96},[],{"intervention":1007,"totalTrials":92,"cells":1008},"Phenylephrine",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1029},{"trials":1010,"activeCount":96},[],{"trials":1012,"activeCount":96},[],{"trials":1014,"activeCount":96},[],{"trials":1016,"activeCount":96},[],{"trials":1018,"activeCount":96},[1019],{"nctId":1020,"briefTitle":1021,"status":585,"phases":1022,"primaryCompletion":1023,"completion":1023,"start":980,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT02354833","Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery",[88],"2015-08",85,[1026],"Effects of; Anesthesia, in Labor and Delivery",[1007,1028],"Norepinephrine",{"trials":1030,"activeCount":96},[],{"intervention":1028,"totalTrials":92,"cells":1032},{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1047},{"trials":1034,"activeCount":96},[],{"trials":1036,"activeCount":96},[],{"trials":1038,"activeCount":96},[],{"trials":1040,"activeCount":96},[],{"trials":1042,"activeCount":96},[1043],{"nctId":1020,"briefTitle":1021,"status":585,"phases":1044,"primaryCompletion":1023,"completion":1023,"start":980,"enrollment":1024,"conditions":1045,"interventions":1046},[88],[1026],[1007,1028],{"trials":1048,"activeCount":96},[],{"intervention":1050,"totalTrials":92,"cells":1051},"Latanoprost ophthalmic solution",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1073},{"trials":1053,"activeCount":96},[],{"trials":1055,"activeCount":96},[],{"trials":1057,"activeCount":96},[],{"trials":1059,"activeCount":96},[],{"trials":1061,"activeCount":96},[1062],{"nctId":1063,"briefTitle":1064,"status":571,"phases":1065,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":96,"conditions":1069,"interventions":1071},"NCT03648229","African Glaucoma Laser Trial",[88],"2022-06-30","2024-06-30","2019-09-01",[1070],"Open-angle Glaucoma",[1050,1072],"Timolol ophthalmic solution",{"trials":1074,"activeCount":96},[],{"intervention":1072,"totalTrials":92,"cells":1076},{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1085,"NA":1091},{"trials":1078,"activeCount":96},[],{"trials":1080,"activeCount":96},[],{"trials":1082,"activeCount":96},[],{"trials":1084,"activeCount":96},[],{"trials":1086,"activeCount":96},[1087],{"nctId":1063,"briefTitle":1064,"status":571,"phases":1088,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":96,"conditions":1089,"interventions":1090},[88],[1070],[1050,1072],{"trials":1092,"activeCount":96},[],{"intervention":1094,"totalTrials":92,"cells":1095},"Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid",{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1122},{"trials":1097,"activeCount":96},[],{"trials":1099,"activeCount":96},[],{"trials":1101,"activeCount":96},[],{"trials":1103,"activeCount":96},[],{"trials":1105,"activeCount":96},[1106],{"nctId":1107,"briefTitle":1108,"status":744,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1120},"NCT05977868","Comparing Oral Versus Parenteral Antimicrobial Therapy",[88],"2025-02-14","2023-08-04",94,[1114,1115,1116,1117,1118,1119],"Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection",[1094,1121],"Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem",{"trials":1123,"activeCount":96},[],{"intervention":1121,"totalTrials":92,"cells":1125},{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1140},{"trials":1127,"activeCount":96},[],{"trials":1129,"activeCount":96},[],{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":96},[],{"trials":1135,"activeCount":96},[1136],{"nctId":1107,"briefTitle":1108,"status":744,"phases":1137,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":1112,"conditions":1138,"interventions":1139},[88],[1114,1115,1116,1117,1118,1119],[1094,1121],{"trials":1141,"activeCount":96},[],{"intervention":1143,"totalTrials":92,"cells":1144},"Spironolactone",{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1164,"NA":1166},{"trials":1146,"activeCount":96},[],{"trials":1148,"activeCount":96},[],{"trials":1150,"activeCount":96},[],{"trials":1152,"activeCount":96},[1153],{"nctId":1154,"briefTitle":1155,"status":1156,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":247,"conditions":1160,"interventions":1163},"NCT01721655","Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease","UNKNOWN",[86,87],"2016-12","2012-10",[1161,1162],"Chronic Lung Disease","Bronchopulmonary Dysplasia",[1143],{"trials":1165,"activeCount":96},[],{"trials":1167,"activeCount":96},[],{"intervention":1169,"totalTrials":92,"cells":1170},"varenicline",{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1190,"NA":1192},{"trials":1172,"activeCount":96},[],{"trials":1174,"activeCount":96},[],{"trials":1176,"activeCount":96},[],{"trials":1178,"activeCount":96},[1179],{"nctId":1180,"briefTitle":1181,"status":585,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1189},"NCT02854800","Smoking Cessation & Opioid Dependence Treatment Integration",[86,87],"2017-04-10","2016-07-08",74,[1187,1188],"Smoking Cessation","Opioid Related Disorders",[1169],{"trials":1191,"activeCount":96},[],{"trials":1193,"activeCount":96},[],{"intervention":1195,"totalTrials":92,"cells":1196},"Convalescent Plasma",{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1201,"PHASE3":1203,"PHASE4":1218,"NA":1220},{"trials":1198,"activeCount":96},[],{"trials":1200,"activeCount":96},[],{"trials":1202,"activeCount":96},[],{"trials":1204,"activeCount":96},[1205],{"nctId":1206,"briefTitle":1207,"status":585,"phases":1208,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1217},"NCT04376034","Convalescent Plasma Collection and Treatment in Pediatrics and Adults",[87],"2021-02-28","2021-04-21","2020-04-16",117,[1214,751,750,1215,1216],"COVID19","Virus Diseases","RNA Virus Infections",[1195],{"trials":1219,"activeCount":96},[],{"trials":1221,"activeCount":96},[],{"intervention":1223,"totalTrials":92,"cells":1224},"Nintedanib",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1242,"NA":1244},{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":96},[],{"trials":1230,"activeCount":96},[],{"trials":1232,"activeCount":96},[1233],{"nctId":1234,"briefTitle":1235,"status":571,"phases":1236,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":96,"conditions":1239,"interventions":1241},"NCT05067517","Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease",[87],"2024-07","2021-11",[1240],"Progressive Fibrosing Interstitial Lung Disease",[1223],{"trials":1243,"activeCount":96},[],{"trials":1245,"activeCount":96},[],{"intervention":1247,"totalTrials":92,"cells":1248},"300 mg Cannabidiol (CBD) oil",{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1250,"activeCount":96},[],{"trials":1252,"activeCount":96},[],{"trials":1254,"activeCount":96},[1255],{"nctId":1256,"briefTitle":1257,"status":585,"phases":1258,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":247,"conditions":1261,"interventions":1265},"NCT04590495","The Effects of Cannabidiol on the Driving Ability of Healthy Adults",[86],"2021-12-01","2021-04-01",[447,1262,1263,1264],"Cognitive Impairment","Sedation Complication","Mood",[1247],{"trials":1267,"activeCount":96},[],{"trials":1269,"activeCount":96},[],{"trials":1271,"activeCount":96},[],{"intervention":1273,"totalTrials":92,"cells":1274},"Nab-paclitaxel",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1276,"activeCount":96},[],{"trials":1278,"activeCount":96},[],{"trials":1280,"activeCount":96},[1281],{"nctId":1282,"briefTitle":1283,"status":571,"phases":1284,"primaryCompletion":1285,"completion":1286,"start":1287,"enrollment":96,"conditions":1288,"interventions":1290},"NCT02405910","Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.",[86],"2017-12","2023-04","2015-03-15",[1289],"Non-small Cell Lung Cancer",[1273,1291],"Gemcitabine",{"trials":1293,"activeCount":96},[],{"trials":1295,"activeCount":96},[],{"trials":1297,"activeCount":96},[],{"intervention":1291,"totalTrials":92,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":96},[],{"trials":1303,"activeCount":96},[],{"trials":1305,"activeCount":96},[1306],{"nctId":1282,"briefTitle":1283,"status":571,"phases":1307,"primaryCompletion":1285,"completion":1286,"start":1287,"enrollment":96,"conditions":1308,"interventions":1309},[86],[1289],[1273,1291],{"trials":1311,"activeCount":96},[],{"trials":1313,"activeCount":96},[],{"trials":1315,"activeCount":96},[],{"intervention":1317,"totalTrials":92,"cells":1318},"Atorvastatin calcium",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1334,"PHASE4":1336,"NA":1338},{"trials":1320,"activeCount":96},[],{"trials":1322,"activeCount":96},[],{"trials":1324,"activeCount":96},[1325],{"nctId":1326,"briefTitle":1327,"status":585,"phases":1328,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":186,"conditions":1331,"interventions":1333},"NCT01175148","Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation",[86],"2014-12","2010-07",[1332],"Graft vs Host Disease",[1317],{"trials":1335,"activeCount":96},[],{"trials":1337,"activeCount":96},[],{"trials":1339,"activeCount":96},[],{"intervention":1341,"totalTrials":92,"cells":1342},"DOXIL",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1344,"activeCount":96},[],{"trials":1346,"activeCount":96},[],{"trials":1348,"activeCount":96},[1349],{"nctId":1350,"briefTitle":1351,"status":585,"phases":1352,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":31,"conditions":1355,"interventions":1357},"NCT00442260","Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer",[85,86],"2008-10","2007-02",[1356],"Metastatic Breast Cancer",[1341,1358],"Abraxane",{"trials":1360,"activeCount":96},[],{"trials":1362,"activeCount":96},[],{"trials":1364,"activeCount":96},[],{"intervention":1358,"totalTrials":92,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1368,"activeCount":96},[],{"trials":1370,"activeCount":96},[],{"trials":1372,"activeCount":96},[1373],{"nctId":1350,"briefTitle":1351,"status":585,"phases":1374,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":31,"conditions":1375,"interventions":1376},[85,86],[1356],[1341,1358],{"trials":1378,"activeCount":96},[],{"trials":1380,"activeCount":96},[],{"trials":1382,"activeCount":96},[],{"intervention":1384,"totalTrials":92,"cells":1385},"The isotope 68Ga, NETSPOT and 18F-FDG-PET\u002FCT",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1387,"activeCount":96},[],{"trials":1389,"activeCount":96},[],{"trials":1391,"activeCount":96},[1392],{"nctId":1393,"briefTitle":1394,"status":585,"phases":1395,"primaryCompletion":1260,"completion":1260,"start":1396,"enrollment":206,"conditions":1397,"interventions":1399},"NCT03602911","A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients",[86],"2019-02-01",[1398],"Head and Neck Squamous Cell Carcinoma",[1384],{"trials":1401,"activeCount":96},[],{"trials":1403,"activeCount":96},[],{"trials":1405,"activeCount":96},[],{"intervention":1407,"totalTrials":92,"cells":1408},"Pimecrolimus",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1410,"activeCount":96},[],{"trials":1412,"activeCount":96},[],{"trials":1414,"activeCount":96},[1415],{"nctId":1416,"briefTitle":1417,"status":744,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1424},"NCT01692626","1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX",[86],"2014-04","2012-02",13,[1423],"Rash",[1407],{"trials":1426,"activeCount":96},[],{"trials":1428,"activeCount":96},[],{"trials":1430,"activeCount":96},[],{"intervention":1432,"totalTrials":92,"cells":1433},"Busulfan",{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1435,"activeCount":96},[],{"trials":1437,"activeCount":96},[],{"trials":1439,"activeCount":96},[1440],{"nctId":1441,"briefTitle":1442,"status":585,"phases":1443,"primaryCompletion":484,"completion":484,"start":1444,"enrollment":12,"conditions":1445,"interventions":1448},"NCT01203020","Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation",[86],"2010-10-12",[1446,1447],"Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma",[1432,1449],"Fludarabine",{"trials":1451,"activeCount":96},[],{"trials":1453,"activeCount":96},[],{"trials":1455,"activeCount":96},[],{"intervention":1449,"totalTrials":92,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1468,"PHASE4":1470,"NA":1472},{"trials":1459,"activeCount":96},[],{"trials":1461,"activeCount":96},[],{"trials":1463,"activeCount":96},[1464],{"nctId":1441,"briefTitle":1442,"status":585,"phases":1465,"primaryCompletion":484,"completion":484,"start":1444,"enrollment":12,"conditions":1466,"interventions":1467},[86],[1446,1447],[1432,1449],{"trials":1469,"activeCount":96},[],{"trials":1471,"activeCount":96},[],{"trials":1473,"activeCount":96},[],{"intervention":1475,"totalTrials":92,"cells":1476},"Ketamine",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1491,"PHASE3":1493,"PHASE4":1495,"NA":1497},{"trials":1478,"activeCount":96},[],{"trials":1480,"activeCount":96},[1481],{"nctId":1482,"briefTitle":1483,"status":1156,"phases":1484,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1490},"NCT04876066","Use of Transmucosal Ketamine in Post Stroke Depression",[85],"2022-11","2020-11-30",21,[1489],"Post-stroke Depression",[1475],{"trials":1492,"activeCount":96},[],{"trials":1494,"activeCount":96},[],{"trials":1496,"activeCount":96},[],{"trials":1498,"activeCount":96},[],{"intervention":1500,"totalTrials":92,"cells":1501},"Eniluracil",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1503,"activeCount":96},[],{"trials":1505,"activeCount":96},[1506],{"nctId":1507,"briefTitle":1508,"status":744,"phases":1509,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":22,"conditions":1512,"interventions":1514},"NCT00827580","Eniluracil Hand Foot Syndrome",[85],"2009-09","2009-01",[19,1513],"Colon Cancer",[1500],{"trials":1516,"activeCount":96},[],{"trials":1518,"activeCount":96},[],{"trials":1520,"activeCount":96},[],{"trials":1522,"activeCount":96},[],{"intervention":1524,"totalTrials":92,"cells":1525},"Carboplatin",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1539,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1527,"activeCount":96},[],{"trials":1529,"activeCount":96},[1530],{"nctId":1531,"briefTitle":1532,"status":744,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":92,"conditions":1536,"interventions":1537},"NCT02252796","Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer",[85],"2017-09","2014-07",[1289],[1524,1538],"Paclitaxel",{"trials":1540,"activeCount":96},[],{"trials":1542,"activeCount":96},[],{"trials":1544,"activeCount":96},[],{"trials":1546,"activeCount":96},[],{"intervention":1538,"totalTrials":92,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1550,"activeCount":96},[],{"trials":1552,"activeCount":96},[1553],{"nctId":1531,"briefTitle":1532,"status":744,"phases":1554,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":92,"conditions":1555,"interventions":1556},[85],[1289],[1524,1538],{"trials":1558,"activeCount":96},[],{"trials":1560,"activeCount":96},[],{"trials":1562,"activeCount":96},[],{"trials":1564,"activeCount":96},[],{"intervention":1566,"totalTrials":92,"cells":1567},"Bevacizumab, CA4P",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1569,"activeCount":96},[],{"trials":1571,"activeCount":96},[1572],{"nctId":1573,"briefTitle":1574,"status":571,"phases":1575,"start":1576,"enrollment":96,"conditions":1577,"interventions":1579},"NCT01052363","OXC401-PO1s\u002FWVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas",[85],"2010-01",[1578],"Central Nervous System Tumors",[1566],{"trials":1581,"activeCount":96},[],{"trials":1583,"activeCount":96},[],{"trials":1585,"activeCount":96},[],{"trials":1587,"activeCount":96},[],{"intervention":1589,"totalTrials":31,"cells":1590},"Carvedilol",{"EARLY_PHASE1":1591,"PHASE1":1613,"PHASE2":1615,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1592,"activeCount":96},[1593,1603],{"nctId":1594,"briefTitle":1595,"status":571,"phases":1596,"primaryCompletion":1597,"completion":1598,"start":1599,"enrollment":96,"conditions":1600,"interventions":1602},"NCT03980249","Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells",[84],"2021-12","2022-06","2020-09",[28,1601],"Glioblastoma Multiforme",[1589],{"nctId":1604,"briefTitle":1605,"status":744,"phases":1606,"primaryCompletion":1607,"completion":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1612},"NCT03861598","Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells",[84],"2020-08-21","2021-06-17","2019-07-19",4,[1601,28],[1589],{"trials":1614,"activeCount":96},[],{"trials":1616,"activeCount":96},[],{"trials":1618,"activeCount":96},[],{"trials":1620,"activeCount":96},[],{"trials":1622,"activeCount":96},[],{"intervention":1624,"totalTrials":92,"cells":1625},"Metformin",{"EARLY_PHASE1":1626,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1627,"activeCount":96},[1628],{"nctId":1629,"briefTitle":1630,"status":744,"phases":1631,"primaryCompletion":1632,"completion":1632,"start":1329,"enrollment":22,"conditions":1633,"interventions":1635},"NCT02402348","Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",[84],"2016-08",[1634],"Cancer of Head and Neck",[1624],{"trials":1637,"activeCount":96},[],{"trials":1639,"activeCount":96},[],{"trials":1641,"activeCount":96},[],{"trials":1643,"activeCount":96},[],{"trials":1645,"activeCount":96},[],{"intervention":1647,"totalTrials":92,"cells":1648},"Immuno-Therapeutic Agent",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1650,"activeCount":96},[],{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[],{"trials":1658,"activeCount":96},[],{"trials":1660,"activeCount":96},[1661],{"nctId":1662,"briefTitle":1663,"status":585,"phases":1664,"primaryCompletion":1066,"completion":1066,"start":1665,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT03035890","Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer",[89],"2017-01-23",35,[1668],"Non Small Cell Lung Cancer Metastatic",[1647],{"intervention":1671,"totalTrials":92,"cells":1672},"prednisolone acetate 1%",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1674,"activeCount":96},[],{"trials":1676,"activeCount":96},[],{"trials":1678,"activeCount":96},[],{"trials":1680,"activeCount":96},[],{"trials":1682,"activeCount":96},[],{"trials":1684,"activeCount":96},[1685],{"nctId":1686,"briefTitle":1687,"status":585,"phases":1688,"completion":1689,"start":1690,"enrollment":1691,"conditions":1692,"interventions":1693},"NCT00406042","The Role of Steroids Following Selective Laser Trabeculoplasty",[89],"2006-06","2005-09",25,[26],[1671],{"intervention":1695,"totalTrials":92,"cells":1696},"Epidural steroid",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":96},[],{"trials":1702,"activeCount":96},[],{"trials":1704,"activeCount":96},[],{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[1709],{"nctId":1710,"briefTitle":1711,"status":744,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":269,"conditions":1715,"interventions":1717},"NCT02239627","Epidural Clonidine Versus Corticosteroid for Low Back Pain",[89],"2015-06","2014-09",[1716],"Back Pain",[1695,1718],"Clonidine",{"intervention":1718,"totalTrials":92,"cells":1720},{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1722,"activeCount":96},[],{"trials":1724,"activeCount":96},[],{"trials":1726,"activeCount":96},[],{"trials":1728,"activeCount":96},[],{"trials":1730,"activeCount":96},[],{"trials":1732,"activeCount":96},[1733],{"nctId":1710,"briefTitle":1711,"status":744,"phases":1734,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":269,"conditions":1735,"interventions":1736},[89],[1716],[1695,1718],{"intervention":1738,"totalTrials":92,"cells":1739},"Lactated Ringer",{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1741,"activeCount":96},[],{"trials":1743,"activeCount":96},[],{"trials":1745,"activeCount":96},[],{"trials":1747,"activeCount":96},[],{"trials":1749,"activeCount":96},[],{"trials":1751,"activeCount":96},[1752],{"nctId":1753,"briefTitle":1754,"status":585,"phases":1755,"primaryCompletion":1756,"completion":1158,"start":1757,"enrollment":1758,"conditions":1759,"interventions":1761},"NCT02638623","Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery",[89],"2016-10","2015-10",52,[1760],"Osteoarthritis",[1738],{"intervention":1763,"totalTrials":92,"cells":1764},"Clindamycin",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1766,"activeCount":96},[],{"trials":1768,"activeCount":96},[],{"trials":1770,"activeCount":96},[],{"trials":1772,"activeCount":96},[],{"trials":1774,"activeCount":96},[],{"trials":1776,"activeCount":96},[1777],{"nctId":1778,"briefTitle":1779,"status":571,"phases":1780,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":96,"conditions":1783,"interventions":1785},"NCT03779295","Laser Therapy for Perioral Dermatitis",[89],"2019-06-05","2018-11-01",[1784],"Perioral Dermatitis",[1763],{"intervention":1787,"totalTrials":92,"cells":1788},"Aspirin",{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1790,"activeCount":96},[],{"trials":1792,"activeCount":96},[],{"trials":1794,"activeCount":96},[],{"trials":1796,"activeCount":96},[],{"trials":1798,"activeCount":96},[],{"trials":1800,"activeCount":96},[1801],{"nctId":1802,"briefTitle":1803,"status":585,"phases":1804,"primaryCompletion":1756,"completion":1756,"start":1805,"enrollment":1806,"conditions":1807,"interventions":1808},"NCT02641080","Evaluating the Need for Pneumatic Compression Devices",[89],"2016-01",80,[1760],[1787],{"intervention":1810,"totalTrials":92,"cells":1811},"Kenalog",{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1813,"activeCount":96},[],{"trials":1815,"activeCount":96},[],{"trials":1817,"activeCount":96},[],{"trials":1819,"activeCount":96},[],{"trials":1821,"activeCount":96},[],{"trials":1823,"activeCount":96},[1824],{"nctId":1825,"briefTitle":1826,"status":585,"phases":1827,"primaryCompletion":1713,"completion":1713,"start":1419,"enrollment":1828,"conditions":1829,"interventions":1831},"NCT02126878","Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection",[89],120,[1830],"Bursitis",[1810],{"intervention":1833,"totalTrials":92,"cells":1834},"Treatment 1; Dexamethasone",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1836,"activeCount":96},[],{"trials":1838,"activeCount":96},[],{"trials":1840,"activeCount":96},[],{"trials":1842,"activeCount":96},[],{"trials":1844,"activeCount":96},[],{"trials":1846,"activeCount":96},[1847],{"nctId":1848,"briefTitle":1849,"status":585,"phases":1850,"primaryCompletion":1851,"completion":1852,"start":1853,"enrollment":1185,"conditions":1854,"interventions":1855},"NCT02416934","Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline",[89],"2016-05-15","2017-05-15","2012-07",[844],[1833,1856],"Treatment 0; Saline placebo",{"intervention":1856,"totalTrials":92,"cells":1858},{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1860,"activeCount":96},[],{"trials":1862,"activeCount":96},[],{"trials":1864,"activeCount":96},[],{"trials":1866,"activeCount":96},[],{"trials":1868,"activeCount":96},[],{"trials":1870,"activeCount":96},[1871],{"nctId":1848,"briefTitle":1849,"status":585,"phases":1872,"primaryCompletion":1851,"completion":1852,"start":1853,"enrollment":1185,"conditions":1873,"interventions":1874},[89],[844],[1833,1856],{"intervention":1876,"totalTrials":92,"cells":1877},"umbilical cord blood",{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1888},{"trials":1879,"activeCount":96},[],{"trials":1881,"activeCount":96},[],{"trials":1883,"activeCount":96},[],{"trials":1885,"activeCount":96},[],{"trials":1887,"activeCount":96},[],{"trials":1889,"activeCount":96},[1890],{"nctId":1891,"briefTitle":1892,"status":585,"phases":1893,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1908},"NCT01768845","Unrelated Umbilical Cord Blood (UBC)Transplantation",[89],"2019-05-14","2021-04-06","2009-02-03",34,[1899,1900,1901,1902,1903,1904,1905,1906,1907],"Chronic Myelogenous Leukemia (CML)","Acute Myelogenous Leukemia (AML)","Myelodysplastic Syndrome","Multiple Myeloma","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia (CLL)","Acute Lymphocytic Leukemia (ALL)","Severe Aplastic Anemia",[1876]]